Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)

2020-04-28T12:38:15+01:00

BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient [...]

Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)2020-04-28T12:38:15+01:00

UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, London

2020-03-03T10:07:02+00:00

• PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR • AAV-RPGR is the only XLRP treatment in development to be awarded P [...]

UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, London2020-03-03T10:07:02+00:00

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

2020-01-30T11:27:30+00:00

Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD BOSTON and LONDON, Jan. 29, 2020 [...]

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)2020-01-30T11:27:30+00:00

Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells

2019-12-17T11:56:35+00:00

Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Techn [...]

Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells2019-12-17T11:56:35+00:00